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A 59-year-old woman was referred to the Fourth Department of
Internal Medicine for evaluation of hypocalcemia. Since the age of 20
years, she has had multiple episodes of numbness and tingling around
the eyes, mouth, and fingertips; these paresthesias sometimes were
accompanied by spasms of the hands. The episodes were more frequent
during menstruation and could be triggered by anxiety. During the
following four decades, these neuromuscular symptoms and signs
persisted but did not inconvenience her, and she did not seek medical
care specifically for these problems. She became pregnant twice in her
early twenties; pregnancy did not significantly change the symptoms.
Both pregnancies resulted in either spontaneous or induced abortion.
She was known to be mildly hypertensive (—1601% mm Hg) since the
fourth decade of life.
During a recent visit to a physician, Trousseau's sign was detected
during blood pressure measurement. A serum calcium determination
was 6.0 mgldl and she was referred to this hospital for further evaluation
and management. The medical history disclosed no neck surgery; no
episodes of convulsion; and no hair, fingernail, or skin abnormalities.
The family history was negative except for pulmonary tuberculosis in
both parents.
On examination, she was alert and oriented with normal mental
function. Height was 148 cm, weight 48 kg, and no gross physical
abnormalities were apparent. Vital signs were within normal limits; the
blood pressure was 125/75 mm Hg. Pertinent physical findings included
the absence of cataracts or any skin and fingernail abnormalities. The
optic fundi were normal. Chvostek and Trousseau signs were present.
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Neurologic examination was within normal limits, Serum chemistry
evaluation revealed: albumin, 4.2 g/dl; sodium, 139 mEq/liter; potas-
sium, 3.5 mEq/liter; chloride, 102 mFq/liter; calcium, 5.5 mgldl; phos-
phate, 4.9 mg/dl; magnesium, 2.4 mg/dl; creatinine, 1.0 mg/dl; and urea
nitrogen, 14 mg/dl. Arterial blood gas had a pH of 7.42; PaCO2, 39.8mm
Hg; and bicarbonate, 25.5 mEq/liter. Other pertinent laboratory data
included an immunoreactive parathyroid hormone (PTH) of 0.5 ng/ml
(C-terminus assay: normal, less than 1.2 at normal serum calcium
levels); 25(OH)D3, 14 ng/ml (normal, 14—42 ng/ml); and I ,25(OH)2D3, 20
pg/mi (normal, 20—60 pg/mi). Metabolic bone x-ray survey was within
normal limits. Cranial x-ray and CT scan showed calcification of basal
ganglia.
An intravenous bolus infusion of human 1—34 PTH promptly in-
creased urinary excretion of cAMP from 0.15 to 19.2 tmol/hr (normal,
0.2—0.4 prnol/hr) and urinary excretion of inorganic phosphate from 19
to 41 mg/hr (Elisworth-Howard test). These data clearly demonstrated
the presence of an adequate renal response to PTH, and established the
diagnosis of idiopathic hypoparathyroidism.
Oral administration of la-hydroxyvitamin D3 [la(OH)D3], 2 sg per
day, was begun and was later increased to 3 jzg per day (Fig. 1). Oral
calcium intake was estimated to be 500 to 700 mg/day. Serum calcium
rose in response to la(OH)D3 administration, but was accompanied by
an increase in urinary calcium excretion that exceeded 250 mg/day
when the serum calcium concentration was only 7.9 to 8.4 mg/dl.
Discussion
DR. KiYosm KUROKAWA (Associate Professor of Medicine,
and Director, Nephrology Division, Fourth Department of
Internal Medicine, University of Tokyo School of Medicine,
Tokyo, Japan): This patient has hypoparathyroidism with char-
acteristic features including hypocalcemia, a low serum para-
thyroid hormone level, low nephrogenous cAMP levels, and
increases in urinary cAMP and inorganic phosphate (Pi) excre-
tion in response to exogenous parathyroid hormone (PTH).
Before I discuss the hypocalcemia and the response to vitamin
D therapy in this patient, I would like to explore with you how
the extracellular (ECF) calcium ion concentration ([Cat ]) is
maintained through the action of the three major calcium-
regulating hormones—PTH, active vitamin D, and calcitonin.
In this presentation, I will not focus on how these hormones
regulate bone cell function and turnover, but rather I will
concentrate on the importance of the actions of these hormones
in the kidney in the regulation of ECF [Cat 1]. In particular, I
plan to spend considerable time discussing the renal action of
caleitonin and its possible physiologic significance, because
these topics are less well clarified and have been dealt with as
minor subjects in many textbooks and review articles. Those
who are interested in broader aspects of ECF [Ca + + I regulation
and abnormalities, skeletal action of calcium-regulating hor-
mones, and other related topics are referred to excellent chap-
ters by Parultt and Kleerekoper [1, 2].
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Fig. 2. Schematic presentation of a conventional view of the regulatory
system for maintaining ECF [Ca + J. In response to a fall in ECF[Ca ], PTH is secreted from parathyroid glands (PTG). PTH acts on
bone and kidney to restore ECF [Ca ],and the stimulation by PTH of
1 ,25-dihydroxyvitamin D (1 ,25D) production in the kidney is necessary
for PTH to activate bone resorption. Although 1 ,25D increases calcium
absorption in the gut, this process is not essential for the steady-state
ECF [Ca ]
8
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Fig. 1. Changes in serum levels and urinary excretion of calcium in
response to administration of I a-hydroxyvitamin D3 in the present
patient. Note a sharp increase in urinary calcium excretion, which
exceeded 200 mg/day even though serum calcium concentration was
subnormal.
In this discussion, I will present evidence to substantiate the
following overall hypothesis: (1) Maintenance of a normal ECF
calcium concentration requires the coordinated actions of PTH,
vitamin D, and calcitonin. (2) To prevent hypocalcemia and to
maintain the steady-state ECF [Cat ÷1 at 5 mg/dl, the integrated
efforts of both PTH and vitamin D are required, both at the
bone-ECF interface and the kidney-ECF interface. (3) Calcito-
nm, the action of which is modulated by vitamin D and
prostaglandins, also acts both at the bone-ECF and the kidney-
ECF interfaces to prevent hypercalcemia and is critical in
depositing orally absorbed calcium in bone, particularly in
conditions of increased bone growth.
Although the balance of total body calcium is maintained
through the regulation of calcium input from the gut and
calcium output in the urine, the steady-state ECF [Ca ] is
determined first by the flux of calcium ions between bone and
ECF, and second by the equilibrium level at which the kidney
reabsorbs filtered calcium and regulates urinary calcium excre-
tion. This entire system is regulated and maintained principally
by the three calcium-regulating hormones. Although calcium
input from the gut can transiently affect ECF [Cat ], it does
not affect the steady-state ECF [Ca + + 1.
The features characteristic of the calcium-regulating endo-
crine system are as follows. First, hypocalcemia develops in the
absence of the calcium-regulating endocrine system. Second,
both PTH and vitamin D raise ECF [Ca ]. Third, both the
PTH and calcitonin systems have sensors that can detect
changes in the ECF [Cat ÷1. Thus, PTH plays a central role in
this regulatory system. Our conventional understanding of the
way the calcium-regulating system maintains ECF [Cat I can
be summarized as follows (Fig. 2). The ECF [Ca } always
tends to fall. This fall is sensed by parathyroid glands, which
then secrete PTH, which in turn acts on the kidney. There PTH
activates the vitamin D system by stimulating 25-hydroxyvita-
mm D3 [25(OH)D3]-la-hydroxylase (1-hydroxylase). Activation
of the vitamin D system leads to increased production of the
active metabolite of vitamin D, 1 ,25-dihydroxyvitamin D3,
[l,25(OH)2D3]. The l,25(OH)2D3 then acts on bone. It is well
known that vitamin D must be present for PTH to cause calcium
release from bone (by activating bone resorption). Thus, the
action of PTH on bone and the kidney, together with the
activation of the vitamin D system in the kidney, restores ECF
[Ca 1 to normal.
Parathyroid hormone, vitamin D, and the kidney
PTHand the kidney. Most of the action of PTH in the kidney
is mediated by activation of membrane-associated adenylate
cyclase, which leads to an increase in cellular cyclic AMP. The
sites of PTH's action along the nephron thus can be deduced by
analyzing the distribution of PTH-sensitive adenylate cyclase.
Using microdissected single-nephron segments, Morel and as-
sociates detected PTH-sensitive adenylate cyclase in proximal
convoluted tubules (PCT), proximal straight tubules (PST), the
cortical portion of thick ascending limbs of Henle, and distal
and connecting tubules [31. Data suggest that in both PCT and
PST, PTH inhibits phosphate reabsorption, thereby resulting in
PTH
ECF Ca*+
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increased urinary phosphate excretion and a lowered serum
phosphate concentration [4]. In addition, PTH inhibits hydro-
gen ion secretion in the proximal tubules, probably by inhibiting
Na-H exchange in the brush border membrane [5—7]. This
inhibition probably leads to an increase in urinary bicarbonate
excretion, and might explain why approximately 20% to 25% of
patients with primary hyperparathyoidism have hyperchloremic
metabolic acidosis [81. Parathyroid hormone stimulates gluco-
neogenesis in the proximal tubules [9, 101, but the significance
of this metabolic process, particularly in the regulation of ECF
[Ca ], is not clear and! will not discuss it further. Parathyroid
hormone also stimulates the production of 1 ,25(OH)2D3 in the
PCI' [111; I will discuss this in more detail. In the distal
nephron, PTH increases tubular reabsorption of calcium [12—
141.
The action of PTH on bone leads to increased dissolution of
hydroxyapatite, which releases calcium, phosphate, and bicar-
bonate into the ECF compartment. At the same time, as I just
menticined, PTH acts on the kidney to inhibit phosphate reab-
sorption and hydrogen secretion; these effects promote urinary
excretion of phosphate and bicarbonate, and decrease steady-
state ECF phosphate and bicarbonate. By contrast, enhanced
calcium release from bone, together with increased tubular
calcium reabsorption, increases ECF [Ca ]. Lower steady-
state ECF phosphate and bicarbonate are advantageous to
raising ECF [Ca I, because increased phosphate can facilitate
precipitation of Ca (with Pi) to soft tissues as well as to bone.
Increased levels of bicarbonate, and thus high pH, tend to
precipitate calcium phosphate at any given level of calcium and
phosphate, Thus, the effects of PTH on renal tubular handling
of these ions can be regarded as an effective mechanism geared
to raising ECF [Ca ÷1.
Activation of the vitamin D system by PTH. Vitamin D3 is
formed in the skin upon exposure to sunlight [15—17]. This
vitamin D3 is hydroxylated in the liver to form 25(OH)D3
[15—17], which is then hydroxylated in the kidney to form
I ,25(OH)2D3 [15—171. The latter reaction in the kidney is cata-
lyzed by 1-hydroxylase, a mitochondrial P450 enzyme. This
1 ,25(OH)2D3 is considered to be the active metabolite of vita-
min D. Renal 1-hydroxylation is the most critical and tightly
regulated component of the process that activates vitamin D
[15—171. Data suggest that PTH is a major activator of renal
1-hydroxylase. Suda and associates showed that 1-hydroxylase
activity in the kidney, determined in vitamin D-deficient rats in
vivo, decreased by 70% to 80% following thyroparathyroidec-
tomy (TPTX), and that the enzyme activity returned to the
pre-TPTX level in response to exogenous PTH or cAMP [18].
In addition, maximal stimulation of 1-hydroxylase by exoge-
nous PTH or cAMP does not differ from the pre-TPTX enzyme
activity, and the maximum effects of exogenous PTH and
cAMP were not additive [18]. These data clearly indicate that in
vitamin D deficiency, stimulation of 1-hydroxylase depends to a
major extent on secondary hyperparathyroidism and that the
enzyme activation is maximized by endogenous PTH. Further,
the data suggest that the stimulation of 1-hydroxylase by PTH is
mediated by cAMP.
Using single-nephron segments dissected from vitamin D-
deficient rats, we showed that the 1-hydroxylase is present only
in PCT and that the enzyme activity is reduced by 70% to 80%
by TPTX [11]. These data, together with the presence of
4 5 6 7 8 9 10 11
Serum cMcium, mg/cl!
Fig. i. Relationship between serum calcium concentration and urinary
calcium excretion in the presence and absence of PTH and vitamin D in
the rat. Note the presence of apparent Tm lor Ca and a threshold serum
Ca concentration, and both PTH and vitamin D independently regulate
the apparent Tm and a threshold Ca concentration. (Adapted from Ref.
21.)
PTH-sensitive adenylate cyclase in the PCT, agree with the
in-vivo data of Suda et al [18] and are consistent with the
concept that the activation of 1-hydroxylase by PTH is medi-
ated by cAMP. I should point out that PTH-sensitive adenylate
cyclase is also present in PST, but no 1-hydroxylase is detect-
able in this nephron segment. Subsequent studies using single-
nephron segments of vitamin D-deficient rats revealed that: (1)
endogenous PTH stimulates 1-hydroxylase in the PCT to its
maximum; (2) exogenous PTH or cAMP restores 1-hydroxylase
activity in the PCT in TPTX rats; and (3) no 1-hydroxylase is
present in the PSI' of vitamin D-deficient rats even in the
presence of excess PTH or exogenous cAMP [19, 20]. These
observations strongly suggest that PTH stimulates 1-hydrox-
ylase in the PCT via cAMP.
Regulation of tubular calcium reabsorption by PTH and
vitamin D. What do we know about the interrelationships
among PTH, vitamin D, and calcium? First, the vitamin D
syStem does not have its own calcium sensor; it uses the PTH
system to detect changes in serum calcium. Second, in vitamin
D deficiency, hypocalcemia develops even though PTH is
present in excess. Third, vitamin D is necessary for PTH to
stimulate bone resorption. Fourth—and this concept is less
widely recognized but firmly established—both PTH and vita-
min D are necessary for normal renal tubular calcium reabsorp-
tion [21]. The last point is best illustrated in Figure 3, which
demonstrates the relationship between the steady-state serum
calcium concentration on the abscissa, and urinary calcium
excretion on the ordinate, in conscious, restrained rats receiv-
ing constant intravenous infusion of fluids containing varying
concentrations of calcium [21]. In the normal state, with both
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PTH and vitamin D present, calcium begins to appear in the
urine when the serum calcium level is normal, that is, 9 to 10
mg/dl. Because any increment in serum calcium above this level
results in urinary calcium excretion, we can assume that there
exists a saturation level for tubular calcium reabsorption, in
effect, a Tm for calcium reabsorption, or a threshold serum
calcium concentration. (The presence of a Tm for tubular
calcium reabsorption in a strict sense is still debated; see Refs.
1 and 2 for review.) Lowering the serum calcium below 9 mg/dl
in the normal state leads to almost complete tubular calcium
reabsorption, and calcium virtually disappears from the urine.
This linear relationship between serum calcium and urinary
calcium shifts to the left in the absence of PTH in vitamin
D-replete rats, consistent with the fact that PTH directly
augments tubular calcium reabsorption. In vitamin D-deficient
rats lacking parathyroid glands (—D, —PTH), this linear rela-
tionship between serum calcium and urinary calcium excretion
shifts even further to the left. On the other hand, in vitamin
D-deflcient TPTX rats, this linear relationship shifts to the right
in response to PTH (—D, +PTH). Even with excess PTH,
however, this relationship does not shift to the right as much as
when both PTH and vitamin D are present (+D, +PTH) [21].
These data clearly indicate that both vitamin D and PTH are
necessary for maintaining normal tubular calcium reabsorption.
In the absence of either one, tubular calcium reabsorption is
incomplete and urinary calcium excretion increases linearly as
the serum calcium concentration rises above 6 mg/dl. Using
these data we can expect that increasing and maintaining the
steady-state serum or ECF [Ca ÷1 at a normal level is difficult
in the absence of either PTH or vitamin D. In the absence of
both PTH and vitamin D, the situation is worse. The site at
which these hormones act to enhance calcium reabsorption is
most likely to be the distal nephron, as shown by micropuncture
and by isolated tubule microperfusion experiments with PTH
[12—141, and as indicated by the presence of vitamin D-depen-
dent calcium binding protein in distal nephron segments [22—
241.
Control of bone and kidney "set points" by PTH and vitamin
D. It is likely that the steady-state ECF [Cat 1] is determined
jointly by the equilibrium of the calcium flux between ECF and
bone and the equilibrium between ECF and the kidney, al-
though the exact nature of this phenomenon is not clear [1].
This overall equilibrium can be regarded as the "set point" for
calcium equilibrium between ECF and bone and calcium equi-
librium between ECF and the kidney. To maintain the steady-
state ECF [Ca ÷1 at a normal level of 5 mg/dl, the individual set
points for the ECF-bone equilibrium and for the ECF-kidney
equilibrium have to be the same; both must be 5 mg/dl. If only
the set-point between ECF and the kidney decreases, and no
change occurs in the set-point between ECF and bone, filtered
calcium is continuously excreted in the urine, and bone contin-
uously pours calcium into the ECF, because the set-point
between the ECF and bone is higher than that between the ECF
and the kidney. This situation brings with it hypercalciuria with
continuous loss of calcium from bone. On the other hand, if the
set-point for calcium is lowered only between the ECF and
bone and not between the ECF and the kidney, urinary calcium
excretion is negligible, and any input of calcium from the gut (or
any other source) is quickly deposited in bone; bone calcium
content thus continues to increase.
These scenarios are rare because of the control of the set
points at both bone and kidney by the integrated efforts of PTH
and vitamin D. These set points are regulated in parallel in
response to alterations in the activities of the PTH and vitamin
D systems. If this were not the case, one of these two
homeostatic systems would be systematically undoing or dis-
turbing the work of the other [1]. Even in hypoparathyroid
patients, net calcium balance is maintained at a lower serum
calcium concentration. Thus calcium input from the intestine is
equal to the urinary calcium excretion, and bone mineral
content does not change significantly [1, 2]. These data indicate
that in the hypoparathyroid steady state, the set-points for both
the bone-ECF flux and the kidney-ECF flux are lowered in
concert to the same level.
Another interesting point is the observation that the set-point
for PTH secretion also seems to be set at an extracellular
calcium concentration of 5 mg/dl. Brown and associates sys-
tematically examined the regulation of PTH secretion using
dispersed parathyroid cells and found that PTH secretion is
about 50% of its maximum at the ambient Ca ++ concentration
of 5 mg/dl and that PTH secretion most sensitively responds to
a deviation in ECF [Cat ] from 5 mg/dl 1251. In addition,
parathyroid glands have specific receptors for 1 ,25(OH)2D3, and
1,25(OH)2D3 can regulate PTH secretion [26, 27]. These obser-
vations suggest that l,25(OH)2D3 may affect the set-point for
PTH secretion in the parathyroid gland; supporting evidence for
this postulate is not yet available. However, a shift of the
set-point for PTH secretion might underlie the development of
the so-called "tertiary" hyperparathyroidism of chronic renal
failure, a shift that, in turn, might be related to the altered
vitamin D metabolism of renal failure. These and other obser-
vations suggest that 1,25(OH)2D3, produced in the kidney and
primarily regulated by PTH, acts on bone, the kidney, and
parathyroid glands, and that these interactions are geared to
maintaining ECF [Ca ] at 5 mg/dl (Fig. 4).
Hypocalcemia in the patient presented
Before discussing the mechanisms of calcitonin's effect on
calcium handling by the kidney, particularly in the setting of
hypercalcemia, I would like to utilize the basic principles
regarding PTH and vitamin D that I have just summarized to
explore the hypocalcemia in this patient. She unequivocally has
hypoparathyroidism and, as a result, hypocalcemia. The low
serum concentration of 1 ,25(OH)2D3 results from the low PTH
level. The most physiologically sound therapeutic modality for
correcting hypocalcemia in this patient would be PTH admin-
istration. But because PTH has to be given parenterally and
perhaps every day, such therapy is not practical. Instead, the
current treatment of choice for correcting the hypocalcemia of
hypoparathyroidism is active vitamin D, l,25(OH)2D3, or an
analogue [such as la(OH)D3], together with an oral calcium
supplement. Such therapy in this patient produced an increase
in the serum calcium level, as expected, and a concomitant
increase in urinary calcium excretion (Fig. 1). The urinary
calcium excretion exceeded 250 mg/day, however, when the
serum calcium reached around 8 mg/dl, a serum calcium level
that is still lower than normal (Fig. 1). Further increases in the
dose of vitamin D are not justified in this patient because more
vitamin D would further increase the urinary calcium excretion
to an unacceptable level and would place her at risk of devel-
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Fig. 4. Schematic presentation of our current concept of the regulatory
system for maintaining ECF[Ca'F J. PTH is secreted from parathyroid
glands (PTG) in response to a fall in ECF [Cat ]. PTH then acts on the
kidney and bone. The I ,25-dihyroxyvitamin D (1 ,25D) produced in the
kidney in response to PTH is essential to regulate the set-points for
renal tubular calcium reabsorption, bone resorption, and PTII se-
cretion.
oping renal stones, nephrocalcinosis, and related morbidity.
This patient thus demonstrates the development of hypercalci-
uria in the presence of lower-than-normal serum calcium in
response to administration of active vitamin D3. Her clinical
course illustrates the fact that the equilibrium, or saturation,
levels of renal tubular calcium reabsorption remain low due to
persistent PTH deficiency. These findings are consistent with
the experimental data I have just reviewed showing that both
PTH and vitamin D are necessary for normal renal calcium
reabsorption and for the maintenance of normal serum [Ca 1.
Thus, restoration of serum calcium to normal in this patient
with vitamin D cannot be accomplished without a significant
side effect, that is, hypercalciuria.
The impaired renal calcium reabsorption that occurred in this
patient during vitamin D therapy, and our inability to com-
pletely restore serum calcium to normal without producing
hypercalciuria, was not unique to this patient, but rather is a
general feature of hypoparathyroidism. Yamamoto and associ-
ates of our Department have described the relationship between
serum calcium level and urinary calcium excretion in patients
with idiopathic hypoparathyroidism (unpublished observations).
It is clear that hypercalciuria is unavoidable if one tries to
normalize the serum calcium level with vitamin D.
Calcitonin, vitamin D, and the kidney
In contrast to the PTH-vitamin D system, which acts primar-
ily to prevent a fall in ECF [Cat ] from the overall equilibrium
level of 5 mgldl, the calcitonin system responds to a rise in ECF
[Ca ]. This situation probably does not occur spontaneously;
as I stated already, ECF [Cat 1 always tends to decrease. The
major action of calcitonin appears to be inhibition of bone
resorption, thus returning an elevated ECF [Cat +] level to
normal.
It has been clearly shown that calcitonin stimulates adenylate
cyclase in bone and kidney. Using isolated single-nephron
segments, Morel [3] and we [28] have demonstrated the pres-
ence of calcitonin-sensitive adenylate cyelase only in the distal
nephron. This finding had strongly suggested that the cAMP-
mediated action of calcitonin is limited to the distal nephron.
But studies of the well-known phosphaturic effect of calcitonin
have established that calcitonin affects the proximal tubule as
well, although not via the mediation of cAMP. We had shown
earlier that both PTH and calcitonin increased urinary phos-
phate excretion in rats that had undergone parathyroidectomy,
and that this increase was preceded by a rise in urinary cAMP
excretion [29]. These data had suggested that cAMP might be a
mediator of the phosphaturic effects of both PTH and calcito-
nm. Subsequent studies have clearly established that the phos-
phaturic effect of PTH is due to inhibition of phosphate reab-
sorption in both PCT and PST and that this effect is mediated by
cAMP [4]. A 1984 micropuncture study demonstrated that
calcitonin inhibits phosphate reabsorption, but only in the PCT
[301. Because the proximal convoluted tubule is devoid of
calcitonin-sensitive adenylate cyclase, the phosphaturic action
of calcitonin in the PCT thus cannot be mediated by cAMP.
Calcitpnin stimulates calcium reabsorption in the distal neph-
ron, and such action might be mediated by cAMP [31, 32]. To
study this possibility, Suki and Rouse perfused isolated rabbi;
medullary thick ascending limb of Henle, a nephron segment
with high calcitonin-sensitive adenylate cyclase activity. These
authors found that calcitonin increases net tubular calcium
reabsorption, and that the effect is mimicked by cAMP. As I
mentioned earlier, with respect to PTH's ability to increase
tubular calcium reabsorption and the set-point for ECF [Cat 1,
one might expect that calcitonin's ability to increase tubular
calcium reabsorption also raises the set-point for ECF [Ca ].
A recent study seems to support this concept. Chronic admin-
istration of calcitonin to hypocalcemic rats that had undergone
thyroparathyroidectomy gradually raised and normalized ECF
[Cat J [33]. This change was accompanied by an elevation of
the serum I ,25(OH)2D3 level, which was low because of thyro-
parathyroidectomy prior to calcitonin administration [33]. Be-
fore returning to the physiologic significance of calcitonin, I will
review the interaction of calcitonin with vitamin D and prosta-
glandins.
Calcitonin and activation of the vitamin D system. We have
shown that calcitonin selectively stimulates 1-hydroxylase in
the PST (Fig. 5) [28]. Because calcitonin had no effect on I-
hydroxylase activity of PCT in both intact and vitamin D-defi-
cient rats that had undergone thyroparathyroidectomy, the data
clearly indicate that calcitonin selectively stimulates 1-hydrox-
ylase in the PST. Calcitonin in the circulation probably is low in
vitamin D deficiency due to hypocalcemia, but is known to be
elevated in the fetus; these data thus explain why 1-hydroxylase
was detected only in PCT in vitamin D-deficient rats, whereas
the enzyme activity was present in both PCT and PST in the
vitamin D-replete fetus [28, 34]. I will return to this point later.
In any event, because PST does not have calcitonin-sensitive
adenylate cyclase, it is clear that caleitonin's ability to stimulate
1-hydroxylase is not mediated by cAMP. This activation of
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Fig. 5. Distribution of calcitonin-sensitive adenylate cyclase (left) and
calcitonin sensitive 25(OH)D3-1-hydroxylase (right) along the nephron
of the thyroparathyroidectomized vitamin D-deficient rat kidney. PCT,
proximal convoluted tubules; PST, proximal straight tubules; MTAL,
medullary thick ascending limbs of Henle; CTAL, cortical thick ascend-
ing limbs of Henle; DT, distal tubules; CT, collecting tubules. (Repro-
duced from Ref. 19.)
1-hydroxylase by calcitonin has been shown not only in vitamin
D-deficient but also in vitamin D-replete rats. Administration of
calcitonin to vitamin D-replete rats that had thyroparathy-
roidectomy thus raises circulating levels of 1,25(OH)2D3 [331.
This effect of calcitonin can be augmented in rats fed a low-
calcium diet [331.
These data demonstrate the presence of two distinct 1-
hydroxylase systems in the kidney [19, 20]. One is localized in
the proximal convoluted tubules, stimulated by PTH via cAMP,
and activated in vitamin D deficiency. The other is localized in
the proximal straight tubules, insensitive to PTH and cAMP,
and selectively stimulated by calcitonin via cAMP-independent
mechanisms.
In summary, the renal effects of calcitonin include inhibition
of phosphate reabsorption in PCT and stimulation of 1-hy-
droxylase in PST, both of which are not mediated by cAMP,
and stimulation of calcium reabsorption in the distal nephron,
probably via cAMP.
Effect of prostaglandin on calcitonin. Matsumoto and asso-
ciates provided data that yielded insights into the cAMP-
independent mechanism by which calcitonin affects proximal
tubular function [35—381. They have shown in the rat that PGE2
infused into the abdominal aorta just above the renal arteries
inhibits the phosphaturic effects of calcitonin, but not of PTH,
whereas PGE2 per se has little phosphaturic effect [36]. Because
the kidney is a rich source of prostaglandins, particularly PGE2,
and because the effect of prostaglandins is thought to be exerted
at the local level [39, 40], it is important to determine whether
the ability of exogenous PGE2 to inhibit the phosphaturic action
of calcitonin indicates a role of endogenous prostaglandins
produced in the kidney. In other words, can endogenous
prostaglandins produced in the kidney modify the phosphaturic
action of calcitonin? Matsumoto and colleagues then demon-
strated that indomethacin administration, which completely
suppressed urinary excretion of PGE2 in the rats, had little
effect on basal urinary phosphate excretion, but markedly
augmented the phosphaturic effects of calcitonin [37]. Thus,
PST/
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Fig. 6. Proposed interactions between PTH, calcironin, and PGE2 on
proximal tubular phosphate transport and activation of 25(OH)D3-Ia-
hydroxylase. PTH via cAMP inhibits phosphate reabsorption in proxi-
mal convoluted tubules (PCT) and proximal straight tubules (PST) and
stimulates I a-hydroxylase in the PCT. Calcitonin, through unknown
mechanisms (?), inhibits phosphate reabsorption in PCT and stimulates
I a-hydroxylase in PST, and the actions of calcitonin on both nephron
segments are inhibited by PGE2 (open arrow), whereas PGE2 per se
stimulates lo-hydroxylase in PCT. (From Ref. 38.)
exogenous PGE2 inhibits, and suppression of endogenous pro-
stagandin production increases, the phosphaturic action of
calcitonin; these findings do suggest that renal prostaglandins
play a physiologically important role in the phosphaturic action
of calcitonin.
Matsumoto and associates further examined the effects of
PGE2, PTH, and calcitonin, each given at maximum concentra-
tion, on the production of 1,25(OH)2D3 in vitamin D-deficient
rats that had had thyroparathyroidectomy [35]. Results from the
studies included the following. (1) Prostaglandin E2 per se
stimulates 1-hydroxylase; (2) PTH and PGE2 have no additive
effects; and (3) PGE2 partially inhibits the stimulatory effect of
calcitonin to the level seen with PGE2 alone. We know that
PTH stimulates 1-hydroxylase in PCT; the data therefore indi-
cate that PGE2 stimulates 1-hydroxylase in PCT; otherwise the
effects of PTH and PGE2 should be additive. The data with
PGE2 and calcitonin therefore strongly suggest that PGE2
completely suppresses calcitonin-dependent 1-hydroxylase ac-
tivation in PST and that the net result is an expression of the
effect of PGE2 in PCT.
The effects of PTH and calcitonin and their modulation by
PGE2 in the proximal tubules are summarized in Figure 6 [38].
Through activation of adenylate cyclase, PTH inhibits phos-
phate reabsorption in both PCT and PST, and it stimulates
1-hydroxylase in PCT. On the other hand, calcitonin, via an
unknown mechanism, inhibits phosphate reabsorption in PCT
and stimulates 1-hydroxylase production in PST. This mecha-
nism of calcitonin's action is inhibited by PGE2, which by itself
may stimulate 1-hydroxylase in PCT.
In addition, the activity of 15—hydroxy prostaglandin dehy-
drogenase, a key enzyme for PGE2 degradation, is highest in
PST [41]. Moreover, the enzyme activity in PST is high in the
young growing rat, and the enzyme activity rapidly decreases
beyond the age of 5 weeks [41]. Because one of the effects of
PGE2 in PST is suppression of the activation of 1-hydroxylase
by calcitonin, these data suggest that the activation of 1-
hydroxylase by calcitonin is highly protected from inhibition by
PGE2 in the young animal by the presence of a highly active
prostaglandin degrading enzyme, and that this protective effect
decreases as the animal gets older. These data support our
concept that calcitonin plays an important role in vitamin D
metabolism in the growing young animals.
Adenylate cyclase
600 400 200
1 a-hydroxylase la-hydroxylaseI PCT
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Physiologic significance of calcitonin
Although the physiologic implication of the PTH-dependent
activation of 1-hydroxylase in the regulation of ECF [Ca ]
and body calcium balance is readily understood, it may not be
immediately clear why calcitonin stimulates 1-hydroxylase. Let
us consider some phylogenic and ontogenic aspects of calcium
regulation [42—44]. From an evolutionary point of view, calci-
tonin is an older hormone than PTH, which is thought to have
evolved only since the organism has adapted to terrestrial life.
In this terrestrial setting, ECF [Ca ] falls in the absence of
PTH. Since both calcitonin and vitamin D systems are found in
some sea animals [45—48], it is possible that the regulation of
1-hydroxylase by calcitonin might be important in certain
primitive life forms like the fetus, which can be considered to be
at an evolutionary stage prior to the stage of adaptation to
terrestrial life. Calcium metabolism in the fetus is characterized
by hypercalcemia, low PTH, and high calcitonin [49—51]. The
fetus makes its own 1 ,25(OH)2D3 in PST [34], although it also
receives it at least in part from the mother [51]. We might
reasonably assume that the '.itamin D system is important for
the fetus to develop its own skeletal system. If the 1-hydrox-
ylase system is regulated primarily by PTH only, then the fetus
might not be able to generate its own 1,25(OH)2D3 under
hypercalcemic and hypoparathyroid conditions in utero. Thus
the presence of calcitonin-dependent 1-hydroxylase in PST may
be of physiologic importance.
Calcitonin also might be physiologically important in the
regulation of calcium metabolism not only in the fetus and the
growing animal, but in the adult as well. As early as 25 years
ago, the physiologic importance of calcitonin in the regulation
of ECF [Cat J in mature animals was recognized [52, 531.
Infusion of EDTA for one hour to a normal dog with intact
thyroparathyroid glands decreased serum calcium; this level
returned to normal within 4 to 6 hours. By the same token, an
infusion of calcium chloride solution for one hour raised serum
calcium, but the serum calcium level returned quickly to normal
within 4 to 6 hours. By contrast, an infusion of the same dose of
EDTA for one hour in animals that had had thyroparathyroid-
ectomy resulted in a greater fall in serum calcium, and the level
did not return to normal for more than 24 hours. Similarly, an
infusion of the same dose of calcium chloride for one hour in
dogs that had had thyroparathyroidectomy resulted in a greater
rise in serum calcium, and its return to normal took more than
24 hours. These data were interpreted correctly to mean that in
response to a fall in serum calcium following EDTA infusion,
PTH was secreted, and through its action on bone and also on
the kidney, serum calcium was quickly restored to normal
within 4 to 6 hours. Without PTH, this process was delayed.
Similarly, a rise in serum calcium triggered calcitonin secretion,
and serum calcium quickly returned to normal, presumably
because calcitonin inhibited bone resorption and deposited
calcium in bone efficiently. In the absence of calcitonin, a rise in
serum calcium following calcium infusion persisted longer than
24 hours because there was no calcitonin to inhibit bone
resorption. Thus in this circumstance, the infused calcium will
not be deposited effectively in bone, and the return of the
elevated serum calcium to normal will depend primarily on
renal calcium excretion. These data clearly demonstrate the
physiologic importance of calcitonin, even in grown subjects.
Moreover, these homeostatic mechanisms of ECF [Ca +J are
also known to be more effective in the young than in the aged
[52].
Secretion of calcitonin in response to a rise in serum calcium
is age-dependent. An increment in serum calcitonin in response
to calcium infusion thus decreases as one gets older [54]. Taken
together, these data show that the secretion and action of
calcitonin are greater in the young than in the old.
Other conditions in which calcitonin may be implicated in the
regulation of vitamin D metabolism are pregnancy and lacta-
tion. Calcitonin and 1 ,25(OH)2D3 levels in the circulation are
elevated during pregnancy and lactation [51, 55—57]. Although
there are many differences in these two conditions, there exist
nonetheless certain similarities in both, such as an increased
demand for calcium and increased intestinal calcium absorp-
tion. Moreover, bone might be protected even through large
quantities of calcium leave the mother through the placenta
during pregnancy and through milk during lactation. Under
these conditions, calcitonin might be important in protecting
bone calcium stores while maintaining intestinal calcium ab-
sorption. An elevation of serum 1 ,25(OH)2D3 might be due, at
least in part, to activation of l-hydroxylase in PST by calcito-
nm. Serum 1 ,25(OH)2D3 levels in lactating rats are higher than
in non-lactating rats even after parathyroidectomy; thus factors
other than PTH might be responsible, at least partly, for high
serum 1 ,25(OH),D3 concentrations. These factors might include
calcitonin and prolactin [55, 56]. In addition, the sites of
1 ,25(OH)2D1 production during these conditions might not be
limited to the kidney. The placenta is endowed with significant
1-hydroxylase activity [58, 59], which might be regulated by
calcitonin.
Scheme for the regulation of calcium metabolism by
calcium-regulating hormones and the kidney
The conventional concept of calcium regulation is depicted
on the right of Figure 7. As I have stated, in the absence of the
calcium-regulating hormones, ECF [Ca ÷1 always falls. A
slight decrease in ECF [Ca ] is sensed by the parathyroid
glands, which then secrete PTH. Parathyroid hormone then
stimulates bone resorption, releasing calcium into the extracel-
lular compartment. At the same time, PTH stimulates renal
tubular calcium reabsorption, thus conserving body calcium.
The actions of PTH need the presence of 1 ,25(OH)2D3, the
production of which is directly stimulated by PTH; l,25(OH)2D1
then acts on the gut to increase calcium absorption and maintain
body calcium balance. In this system of calcium regulation, we
maintain ECF [Cat 4] utilizing bone as a reservoir; this reser-
voir is maintained by increased calcium absorption from the gut
via PTH-dependent I ,25(OH)2D3 production. According to this
model, bone calcium stores can never increase, will be kept
constant at best, and will decrease slowly over the years.
On the other hand, calcium enters our bodies only from the
gut. A meal containing calcium is accompanied by a transient
rise in ECF [Cat i. In response to this small but transient rise
in ECF [Ca ], calcitonin is secreted and ECF [Ca 1 quickly
returns to normal [60, 611, because calcitonin inhibits bone
resorption, as depicted on the left of Figure 7. (Although basal
PTH secretion will be suppressed by hypercalcemia, this de-
crease is not sufficient to account for a rapid lowering of ECF
Fig. 7. Our concept of the calcium-regulating systems in which PTH(right) and calcitonin (left) act as primary sensors and regulators. In
both systems vitamin D activation is essential. The PTH system
defends a fall in ECF [Ca ] and maintains it together with body
calcium balance, utilizing bone as the calcium reservoir. In contrast, the
calcitonin (CT) system responds to a transient rise in ECF [Ca ÷1
following each transient input of calcium from the gut and transfer of
ECF [Ca 4] effectively to bone, an event essential for skeletal growth.
The shaded arrows indicate an overall flow of Ca
[Ca ] to normal [42].) This process thus causes a net deposi-
tion of calcium into bone. The activity of this chain of events is
high in young, growing individuals, as indicated by the age-
dependence of calcitonin secretion in response to calcium
infusion. The high activity of this system allows an effective net
accumulation of calcium into bone, which is essential for
growth of the skeleton. The system is further aided by the
activation of the vitamin D system by calcitonin, which is
clearly protected in the fetus (and probably in the young) from
suppression by prostaglandins because of the high activity of
prostaglandin-degrading enzyme in PST. This activation of the
vitamin D system further results in a highly active and effective
method for calcium accumulation in the body of the growing
individual. Viewed this way, we realize how critical the kidney
is in the regulation of calcium metabolism and ECF [Ca ].
Summary
I have reviewed the conventional view that the PTH-vitamin
D axis is critical in preventing a fall in ECF [Ca ] from its
steady-state value of 5 mgldl and in utilizing the skeletal system
as a calcium reservoir. In this control system, the actions of
PTH and vitamin D on the bone-ECF and the kidney-ECF
interfaces are regulated in a concerted manner. I have advanced
the hypothesis that the calcitonin-vitamin D axis is important
for effective deposition in bone of calcium absorbed from the
gut, the only physiologic route of entry of calcium into the
body, and I have proposed that this effect of calcitonin (that is,
to promote calcium deposition in bone) is particularly important
in conditions in which the body's demand for calcium is
increased, such as in the fetus, the growing individual, and the
female during pregnancy and lactation.
Questions and answers
DR. MIcHIK0 YAMAMOTO (Staff Physician, Health Service
Center, University of Tokyo and the Fourth Department of
Internal Medicine, University of Tokyo School of Medicine,
Tokyo, Japan): Dr. Kurokawa has asked me to present some of
our recent data demonstrating a difference in the renal tubular
Fig. 8. Relationships between serum calcium concentration and urinary
calcium excretion in 3 patients with idiopathic hypoparathyroidism
(broken lines) and 3 patients with pseudohypoparathyroidism (solid
lines) during la-hydroxyvitamin D therapy. Data are the mean SD of
several data points. The hatched area represents a normal range. Note
that the renal tubular calcium reabsorption is within normal limits in
pseudohypoparathyroid patients, whereas it is incomplete in patients
with idiopathic hypoparathyroidism. Because of this difference, signif-
icant hypercalciuria ensues in response to vitamin D therapy with
subnormal serum calcium levels in the latter. Urinary calcium excretion
is expressed as mg per 100 ml glomerular filtrate (GF).
calcium handling between idiopathic and pseudohypoparathy-
roidism. The relationship between serum calcium and urinary
calcium excretion differs between idiopathic hypoparathyroid and
pseudohypoparathyroid patients during therapy with 1 a(OH)D3
(Fig. 8). The apparent threshold or set-point for tubular calcium
reabsorption (or an "apparent Tm for calcium reabsorption")
is, in general, lower in idiopathic hypoparathyroidism than in
pseudohypoparathyroidism. Moreover, in contrast to patients
with idiopathic hypoparathyroidism, urinary calcium excretion
at near-normal serum calcium levels in pseudohypoparathyroid
patients is comparable to that in normal subjects. These data
strongly suggest that renal tubular calcium reabsorption is
normal in pseudohypoparathyroidism, but abnormal in idio-
pathic hypoparathyroidism, when patients are normocalcemic
with vitamin D treatment. It should be noted, however, that
increases in urinary phosphate and cAMP in response to
exogenous PTH were still absent in these pseudohypoparathy-
roid patients receiving la(OH)D3. Because it is likely that
cAMP and phosphaturic responses represent proximal tubular
effects of PTH and that calcium reabsorption represents a distal
tubular effect of PTH, as discussed by Dr. Kurokawa, these
data suggest that the action of PTH in proximal tubules is
impaired, but that its action in distal tubules is not impaired in
pseudohypoparathyroidism.
To further test this possibility, we analyzed changes in
urinary calcium excretion in response to exogenous PTH. We
found that urinary calcium excretion decreased similarly in both
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idiopathic and pseudohypoparathyroidism. Our findings indi-
cated that PTH increases distal calcium reabsorption equally in
both groups of patients while they received 1 a(OH)D3. Thus
both endogenous and exogenous PTH are effective in increasing
calcium reabsorption in the distal nephron in pseudohypo-
parathyroidism. It has been suggested that the defective gua-
nine nucleotide regulatory protein, or N-protein, might be
responsible, at least in part, for the PTH resistance of pseudo-
hypoparathyroidism [62, 631. It is likely that a comparable
defect in N-protein exists in both the proximal and distal
nephron in these patients. The resistance to PTH in the proxi-
mal nephron and the presence of normal FFH action in the
distal nephron in pseudohypoparathyroidism raise the possibil-
ity that the PTH receptor system in the distal nephron can
function independently of adenylate cyclase activation.
Without vitamin D therapy, patients with pseudohypopara-
thyroidism are hypocalcemic, and their tubular calcium reab-
sorption is abnormal. This abnormality is not due to the
resistance of the distal nephron to PTH, but rather to the
defective production of active vitamin D in the proximal neph-
ron, which is resistant to FF1!. The ability of PTH to stimulate
tubular calcium reabsorption returns to normal when active
vitamin D is provided and serum calcium levels become normal,
as shown in our patients. This postulate is consistent with our
data in the rat, which show that both PTH and vitamin D are
necessary for normal tubular calcium reabsorption [211. By
contrast, as shown in our patients, renal calcium handling
remains abnormal in idiopathic hypoparathyroidism, even dur-
ing therapy with la(OH)D3, because of the absence of PTH.
Thus, urinary calcium excretion increases markedly, and even
serum calcium concentration is below normal during vitamin D
therapy. This becomes a major clinical problem in that one
cannot normalize the serum calcium concentration without
inducing hypercalciuria; the hypercalciuria may facilitate the
development of nephrocalcinosis and renal stone formation,
thus limiting the use of vitamin D therapy, as Dr. Kurokawa
pointed out.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): Dr. Yamamoto,
you have shown that urinary calcium excretion in response to
exogenous PTH is comparable in idiopathic and pseudohypo-
parathyroidism. Given the higher circulating levels of PTH in
pseudohypoparathyroid patients, I would expect that these
patients would demonstrate blunted or lesser responses to
exogenous PTH compared with idiopathic hypoparathyroid
patients, in part because of the down-regulation of hormone
receptors.
DR. YAMAMOTO: Before treatment with l(OH)D3, the uri-
nary calcium response to exogenous PTH was apparently
blunted in pseudohypoparathyroid patients. However, during
treatment with la(OH)D3, their circulating PTH levels de-
creased to almost normal levels, and the response in urinary
calcium excretion to exogenous PTH is almost equal to that
seen in idiopathic hypoparathyroidism. However, prior to vita-
min D treatment, patients with idiopathic hypoparathyroidism
did not show an exaggerated hypocalciuric response either.
Because of a very low baseline urinary calcium excretion in
both idiopathic and pseudohypoparathyroidism, one cannot
detect a further decrease in urinary excretion in response to
exogenous PTH. Thus any data on the effects of PTH on
urinary calcium excretion in hypoparathyroidism without vita-
min D therapy must be interpreted carefully. Because of these
reasons, we could not discern from our data whether PTH can
stimulate calcium reabsorption in pseudohypoparathyroid pa-
tients without vitamin D. It is clear, however, that stimulation
of tubular calcium reabsorption was normal in pseudohypopara-
thyroidism in the presence of l,25(OH)2D3. As you might
expect, the phosphaturic response to exogenous FF11 was
absent in pseudohypoparathyroid patients even in the presence
of l,25(OH)2D3.
DR. KUROKAWA: Data suggest that the down-regulation of
hormone receptors might be mediated by phosphorylation of
hormone receptor molecules, a process which, for some recep-
tors, might be mediated by cAMP. If this is the case with PTH
receptors, and if PTH's ability to increase calcium reabsorption
in the distal tubule is independent of cAMP, as Dr. Yamamoto
suggested, then there might not be a comparable down-regu-
lation of PTH receptors in the distal nephron, as cAMP might
not be produced in pseudohypoparathyroidism even prior to
vitamin D therapy.
DR. KENMEI TAKAICHI (Clinical Associate, Fourth Depart-
ment of Internal Medicine, University of Tokyo School of
Medicine): Because PTH is known to decrease proximal bicar-
bonate and phosphate reabsorption, one might expect that a low
serum bicarbonate or hyperchloremic metabolic acidosis is
present with a comparable frequency with hypophosphatemia
in primary hyperparathyroidism. However, as you mentioned,
the incidence of low serum bicarbonate in these patients is only
20% to 25%. Can you explain this discrepancy?
DR. KUROKAWA: Several explanations exist for this seem-
ingly discrepant expression of PTH's action in the proximal
nephron. There is little doubt that excess PTH inhibits proximal
bicarbonate reabsorption or hydrogen ion secretion and causes
some bicarbonaturia. The magnitude of bicarbonaturia may not
be sufficient to result in a steady-state low serum bicarbonate,
however. Also, hypercalcemia per se stimulates, and low serum
phosphate per se might impair, proximal bicarbonate reabsorp-
tion. Thus at least three factors exert opposing effects on
proximal bicarbonate reabsorption in primary hyperparathy-
roidism, and the serum bicarbonate might be determined as a
net effect of these factors [8]. This interpretation is supported
by the fact that the hypercalcemia of malignancy, in which
hypercalcemia is present with low PTH, is often associated with
high serum bicarbonate or metabolic alkalosis.
DR. TosHlo MATSUMOTO (Clinical Associate, Fourth De-
partment of Internal Medicine, University of Tokyo School of
Medicine): You mentioned that the vitamin D system might not
have its own sensor for ECF [Ca J. In the absence of FF11,
however, hypocalcemia per se can stimulate, and hypercalce-
mia per se can inhibit, the renal production of 1 ,25(OH)2D3. We
recently showed that renal 1 -hydroxylase activity is elevated in
hypocalcemic rats that have undergone thyroparathyroidecto-
my f64]. Thus, I believe that your statement that the vitamin D
system utilizes the PTH system as its calcium sensor may be
too simplistic.
DR. KUROKAWA: Your point is well taken. It is true that even
in the absence of PTH, renal 1-hydroxylase activity can be
stimulated by hypocalcemia and inhibited by hypercalcemia
[64, 65]. However, these processes may take considerably
longer than does regulation by PTH, and I believe that the PTH
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system is a more important physiologic regulator of vitamin D
activation in the kidney.
DR. MATSUMOTO: You mentioned that calcitonin may stim-
ulate 1 -hydroxylase both in vitamin D-deficient as well as in
vitamin D-replete patients, as shown by Jaeger et a! [33].
However, there are reports of normal serum l,25(OH)2D3 levels
in patients with medullary carcinoma of the thyroid despite
their elevated circulating calcitonin levels [66]. Could you
comment on this apparent discrepancy?
DR. KUROKAWA: Other data indicate that serum I ,25(OH)2D3
may be elevated in patients with medullary carcinoma of the
thyroid [671. It is possible that the elevation of serum I ,25(OH)2D3
depends on whether the patient has sustained hypercalcitoni-
nemia or episodic bursts of exaggerated calcitonin secretion.
Another point to consider is that many patients with medullary
carcinoma of the thyroid have multiple endocrine adenomatosis,
which is accompanied by parathyroid hyperplasia. Thus even
though a patient might have an elevated serum 1 ,25(OH)2D3,
the increase might be due to excess PTH rather than to excess
calcitonin.
DR. HARRINGTON: What factors account for the different
response of calcitonin secretion to calcium infusion in men and
women? Is the difference due to testosterone or possibly to
female sex hormones?
DR. KUROKAWA: Data suggest that sex hormones affect renal
1-hydroxylase activity [15—171. I am not aware of any data
definitively demonstrating the role of sex hormones in calci-
tonin secretion. Nonetheless, if calcitonin is important as a
calcium-conserving hormone, the lower calcitonin secretion in
females might be responsible, at least in part, for lower bone
mineral content in the female.
DR. HIR0sHI MATSUNAGA (Clinical Associate, Fourth De-
partment of Internal Medicine, University of Tokyo School of
Medicine): In idiopathic hypoparathyroidism, bone mineral
content is not always grossly abnormal. How could hypopara-
thyroid children maintain normal skeletal growth and normal
bone mineral content in the absence of PTH?
DR. KUROKAWA: I do not know. These children have low but
definite quantities of vitamin D, which might be regulated
independently of PTH. This level of active vitamin D possibly is
sufficient for normal skeletal growth. Further, a demand for
calcium in growing individuals might be met even in the absence
of PTH. In addition, certain growth factors might play an
important role in the regulation of skeletal growth, bone resorp-
tion, and ECF [Cat 1. These factors include transforming
growth factors and epidermal growth factors, as it has been
shown that these growth factors stimulate bone resorption [68,
69].
DR. YAMAMOTO: In my experience, skeletal growth and bone
mineral content seem grossly normal even in children with
early-onset hypoparathyroidism. It is possible that as long as
positive calcium balance is maintained during this growing
period, bone can accomplish almost normal growth even in the
absence of PTH.
DR. HARRINGTON: Long-term dialysis patients often have
hypocalcemia, hyperphosphatemia, and high levels of circulat-
ing PTH. Occasional patients, however, develop overt hyper-
calcemia, the so-called "tertiary" or "autonomous" hyper-
parathyroidism, with massive parathyroid glandular hyperpla-
sia. What happens to calcitonin levels in this situation?
DR. KUROKAWA: Patients with chronic renal failure can have
elevated serum calcitonin levels despite the presence of hypo-
calcemia. However, analyses of the serum immunoreactive
calcitonin in these patients show the presence of multiple
fragments. It has not been clarified whether the high circulating
immunoreactive calcitonin level in chronic dialysis patients is
always accompanied by elevated levels of the biologic active
fragment of calcitonin in the circulation. Jam not aware of data
definitively demonstrating the elevation of intact calcitonin in
long-term dialysis patients or data showing changing calcitonin
levels before and after the development of "autonomous"
hyperparathyroid hyperplasia.
Nonetheless it is of interest how these patients develop
hypercalcemia due to parathyroid hyperplasia, because the
stimulus for PTH hypersecretion in these patients must be
hypocalcemia. As I pointed out briefly, there seems to be a
set-point of PTH secretion, and this set point might shift to the
right in some dialysis patients [25]. In these patients, PTH
secretion might not be suppressed even in the presence of
normal ECF [Ca ]. It may well be that "tertiary" hyperpara-
thyroidism might represent a shift of the set-point of PTH
secretion. The mechanism by which this shift of set-point is
brought about is not known. Because PTH secretion might be
regulated by both l,25(OH)2D3 and 24,25(OH)2D3 [15, 17], and
because these two vitamin D metabolites are chronically defi-
cient in long—term dialysis patients, it is possible that the
combination of the deficiency of these two metabolites, to-
gether with the uremic environment, might be responsible for
the development of massive parathyroid hyperplasia with a shift
of the set-point. I do not believe that the magnitude of parathy-
roid hyperplasia in chronic dialysis patients is encountered in
other chronic hypocalcemic conditions that stimulate PTH
secretion chronically, such as vitamin D deficiency.
Another interesting problem in long-term dialysis patients is
the recent finding that 1 ,25(OH)2D3 sometimes is detected even
in patients who have undergone nephrectomy [70]. This obser-
vation indicates the presence of extrarenal 1-hydroxylase in
these patients. Recent data suggest the presence of 1-hydrox-
ylase in certain tissues, including placenta, stimulated macro-
phages in sarcoidosis, and human bone cells in culture [15, 17].
Nonetheless, rigorous attempts have failed to demonstrate the
presence of extrarenal 1-hydroxylase in vitamin D-deficient rats
[71]. I should note, however, that according to our current
thesis of the presence of two distinct 1-hydroxylase systems,
the calcitonin-sensitive 1-hydroxylase in PST is dormant in
vitamin D deficiency. We propose the possibility that the
extrarena! 1-hydroxylase represents predominantly the 1-hy-
droxylase that is insensitive to PTH but sensitive to other
factors, such as calcitonin, that possibly are not present in vitamin
D deficiency [19, 20, 72]. This thesis explains why l-hydroxylase
activity could not be detected in nephrectomized vitamin D-
deficient animals [71]. If we are correct, the I ,25(OH)2D3
present in the circulation in nephrectomized dialysis patients
might be derived from bone cells in which 1 -hydroxylase might
be stimulated not by PTH but by calcitonin [721.
As I mentioned, the possible physiologic implications of
calcitonin-sensitive 1-hydroxylase may become manifest in
certain physiologic conditions such as pregnancy and lactation.
Expression of bone cell 1-hydroxylase in dialysis patients, if
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proven to be calcitonin sensitive, might represent an aberrant
expression of the calcitonin-sensitive 1-hydroxylase.
DR. MAKOTO SUZUKI (Clinical Associate, Second Depart-
ment of Internal Medicine, Jikei Medical College, Tokyo): I am
very much interested in the modulation of calcitonin's action in
the proximal nephron by PGE2. Do you have any data on the
cellular mechanism by which calcitonin regulates proximal
tubular function? Is it intracellular calcium?
DR. KUROKAWA: The effect of calcitonin on 1-hydroxylase in
the PST is a direct one, as calcitonin stimulates enzyme activity
in the primary culture of rat cortical tubules [73]. The mecha-
nism of this signal transduction is not known, and we thought
about the possibility of changes in intracellular calcium, intra-
cellular phosphate, the protein kinase C system, and cGMP, but
we have no data at present to support or refute these possibil-
ities. At the least, we know that PGE2 modulates this cellular
mechanism, probably acting at the level of the plasma mem-
brane of the proximal nephron.
DR. HARRTNGTON: Do you think a long-acting human PTH
preparation is a step forward in the treatment of hypopara-
thyroid patients, and is such a preparation under development?
DR. KUROKAWA: I believe that such a preparation will be a
definite advantage in the treatment of hypoparathyroidism. I am
not aware of the presence or availability of such a preparation
at present.
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